AstraZeneca Vaxzevria® PASS

AstraZeneca Vaxzevria® PASS

This project was required by PRAC and aims to identify, characterise, and quantify the risk of safety concerns and AESIs from the AstraZeneca Vaxzevria® vaccine across large and diverse populations. The study includes data from 5 European sites across 4 different countries within the VAC4EU network.

Registration and Protocol
EUPAS43556. Rebordosa C et al. A post-authorisation/post-marketing observational study to evaluate the association between exposure toAZD1222and safety concernsusing existing secondary health data sources. 10 October 2022.